Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arcus Biosciences : Wedbush Adjusts Price Target on Arcus Biosciences to $52 From $55, Keeps Outperform Rating

03/01/2021 | 07:16am EST


© MT Newswires 2021
All news about ARCUS BIOSCIENCES, INC.
11/24Arcus Biosciences Announces New Employment Inducement Grants
BU
11/22Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conferenc..
BU
11/19Berenberg Bank Adjusts Arcus Biosciences' Price Target to $68 From $60, Maintains Buy R..
MT
11/19Citigroup Adjusts Price Target on Arcus Biosciences to $53 From $42, Reiterates Buy Rat..
MT
11/19Barclays Adjusts Price Target on Arcus Biosciences to $60 From $48, Keeps Overweight Ra..
MT
11/19Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to..
MT
11/18Health Care Stocks Ending Little Changed in Quiet Trading
MT
11/18Arcus Biosciences Shares Rally as Gilead Exercises Options
DJ
11/18Gilead Exercises Option to Co-Develop Three Arcus Biosciences Clinical-Stage Cancer Pro..
MT
11/18SVB Leerink Adjusts Price Target on Arcus Biosciences to $100 From $68, Maintains Outpe..
MT
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 169 M - -
Net income 2021 -248 M - -
Net cash 2021 1 053 M - -
P/E ratio 2021 -12,8x
Yield 2021 -
Capitalization 3 257 M 3 257 M -
EV / Sales 2021 13,0x
EV / Sales 2022 11,6x
Nbr of Employees 236
Free-Float 62,7%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 46,36 $
Average target price 64,60 $
Spread / Average Target 39,3%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.78.58%3 257
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431